ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00750841
Recruitment Status : Active, not recruiting
First Posted : September 11, 2008
Last Update Posted : January 30, 2018
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : July 30, 2009
  Estimated Study Completion Date : December 31, 2018